The present study identified five potential biomarker genes (TOX, DNM3, KLHL42, PGM2L1, and SESN3) that were specifically overexpressed in both blood- and skin-derived SCs and could help to distinguish between SS and PE patients. This evidence concerns the gene TOX and synovial sarcoma.